Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01299-18. doi: 10.1128/AAC.01299-18. Print 2018 Oct.

In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Author information

1
Center for Emerging and Reemerging Infectious Diseases and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA smithra@u.washington.edu.
2
Center for Emerging and Reemerging Infectious Diseases and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
3
Service des Maladies Infectieuses et Tropicales, CHNU de Fann, Dakar, Senegal.
4
Department of Global Health, University of Washington, Seattle, Washington, USA.

Abstract

We examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. HIV-2 was sensitive to cabotegravir in single-cycle and spreading-infection assays, with 50% effective concentrations (EC50s) in the low to subnanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.

KEYWORDS:

HIV-2; PrEP; West Africa; antiretroviral therapy; cabotegravir; human immunodeficiency virus; treatment

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center